189 related articles for article (PubMed ID: 20836875)
1. Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
Doloff JC; Su T; Waxman DJ
BMC Cancer; 2010 Sep; 10():487. PubMed ID: 20836875
[TBL] [Abstract][Full Text] [Related]
2. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2004 Jan; 64(1):292-303. PubMed ID: 14729637
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
Jounaidi Y; Chen CS; Veal GJ; Waxman DJ
Mol Cancer Ther; 2006 Mar; 5(3):541-55. PubMed ID: 16546968
[TBL] [Abstract][Full Text] [Related]
4. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
Schwartz PS; Chen CS; Waxman DJ
Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909
[TBL] [Abstract][Full Text] [Related]
5. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.
Tychopoulos M; Corcos L; Genne P; Beaune P; de Waziers I
Cancer Gene Ther; 2005 May; 12(5):497-508. PubMed ID: 15746946
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
Chen L; Yu LJ; Waxman DJ
Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
[TBL] [Abstract][Full Text] [Related]
7. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer.
Kan O; Griffiths L; Baban D; Iqball S; Uden M; Spearman H; Slingsby J; Price T; Esapa M; Kingsman S; Kingsman A; Slade A; Naylor S
Cancer Gene Ther; 2001 Jul; 8(7):473-82. PubMed ID: 11498768
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
9. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
10. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.
Chen CS; Jounaidi Y; Su T; Waxman DJ
Cancer Gene Ther; 2007 Dec; 14(12):935-44. PubMed ID: 17853921
[TBL] [Abstract][Full Text] [Related]
12. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
Braybrooke JP; Slade A; Deplanque G; Harrop R; Madhusudan S; Forster MD; Gibson R; Makris A; Talbot DC; Steiner J; White L; Kan O; Naylor S; Carroll MW; Kingsman SM; Harris AL
Clin Cancer Res; 2005 Feb; 11(4):1512-20. PubMed ID: 15746054
[TBL] [Abstract][Full Text] [Related]
14. Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo.
Nguyen TA; Tychopoulos M; Bichat F; Zimmermann C; Flinois JP; Diry M; Ahlberg E; Delaforge M; Corcos L; Beaune P; Dansette P; André F; de Waziers I
Mol Pharmacol; 2008 Apr; 73(4):1122-33. PubMed ID: 18212249
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.
Zhou D; Lu Y; Steiner MS; Dalton JT
Antimicrob Agents Chemother; 2000 Oct; 44(10):2659-63. PubMed ID: 10991840
[TBL] [Abstract][Full Text] [Related]
16. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma.
Mercapide J; Rappa G; Anzanello F; King J; Fodstad O; Lorico A
Int J Cancer; 2010 Mar; 126(5):1206-15. PubMed ID: 19653275
[TBL] [Abstract][Full Text] [Related]
17. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
Rainov NG; Dobberstein KU; Sena-Esteves M; Herrlinger U; Kramm CM; Philpot RM; Hilton J; Chiocca EA; Breakefield XO
Hum Gene Ther; 1998 Jun; 9(9):1261-73. PubMed ID: 9650611
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Chen L; Waxman DJ
Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
[TBL] [Abstract][Full Text] [Related]
19. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
[TBL] [Abstract][Full Text] [Related]
20. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
Günther M; Waxman DJ; Wagner E; Ogris M
Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
